Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

548.25 +0.96 (+0.17%)
Streaming Delayed Price Updated: 2:39 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
76 77 Next >
News headline image
Vertex Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Which S&P500 stocks have an unusual volume on Wednesday? ↗
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Strong Affordable Growth Pick with Solid Fundamentals ↗
Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors. 
Via Chartmill
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity ↗
Via Stocktwits
News headline image
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip ↗
There's more good news than bad news for this big biotech stock. 
Via The Motley Fool
Topics Earnings
News headline image
Market Monitor News August 06 BMO - Wall Street Slides as Services Sector Falters, but Palantir Rockets Past Expectations ↗
A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red. 
Via Chartmill
Topics Economy
News headline image
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial.... 
Via StockStory
Topics Artificial Intelligence
News headline image
Top S&P500 movers in Tuesday's session ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
News headline image
Weakness In Vertex Stock Seen As Buying Opportunity ↗
Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales. 
Via Benzinga
News headline image
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results ↗
 
Via Benzinga
News headline image
Stock Market Rollercoaster: Wall Street Navigates Sharp Swings and Rebounds in Early August
The financial markets have been on a tumultuous ride in early August 2025, experiencing a dramatic "see-saw" pattern that has left investors both wary and hopeful. Following a sharp decline at the... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which S&P500 stocks have an unusual volume on Tuesday? ↗
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Which S&P500 stocks are moving on Tuesday? ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index. 
Via Chartmill
News headline image
Assessing Vertex Pharmaceuticals: Insights From 9 Financial Analysts ↗
 
Via Benzinga
News headline image
Discover the top S&P500 movers in Tuesday's pre-market session. ↗
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
News headline image
These stocks are moving in today's pre-market session ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993 ↗
Vertex Pharmaceuticals announces financial results for the second quarter after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Monday? ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Stock Plummets 13% After Discontinuing VX-993 Despite Q2 Earnings Beat ↗
Vertex Q2 2025 earnings beat estimates, but stock dropped 13% after discontinuing acute pain drug VX-993. Focus remains on CF and other key programs. 
Via Chartmill
Topics Earnings
News headline image
Vertex Crashes After Pain Drug Flop Outweighs Second-Quarter Beat ↗
Vertex stock crashed late Monday after the company said it wouldn't advance a next-generation pain drug into more testing. 
Via Investor's Business Daily
Topics ETFs
News headline image
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q2 Sales Beat Estimates But Stock Drops 13.5%
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full... 
Via StockStory
Topics Earnings
News headline image
Vertex Reports Second Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.